Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
Show more...
CEO
Mr. Magnus Christensen
직원
9
국가
스웨덴
ISIN
SE0000273294
WKN
000903662
상장
0 Comments
생각을 공유하기
FAQ
오늘 Medivir AB (publ) 주가는 얼마인가요?▼
MVIR-B.ST의 현재 가격은 SEK7.22 SEK이며, 지난 24시간 동안 +0% 상승했습니다. 차트에서 Medivir AB (publ) 주가 흐름을 더 자세히 살펴보세요.
Medivir AB (publ)의 주식 심볼은 무엇인가요?▼
거래소에 따라 주식 심볼이 다를 수 있습니다. 예를 들어, 거래소에서는 Medivir AB (publ) 주식이 MVIR-B.ST 심볼로 거래됩니다.